MedPath

Frequency of occurrence by risk-based response to infusion reaction upon rituximab administration in patients with B-cell non-Hodgkin's lymphoma

Not Applicable
Conditions
B-cell non-Hodgkin&#39
s lymphoma
Registration Number
JPRN-UMIN000032309
Lead Sponsor
ihon University Itabashi Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
83
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who have been treated with rituximab in the past

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence rate of infusion reaction in each risk group at the time of initial administration of rituximab
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath